How Researchers Are Improving Islet Cell Survival Post-transplant

Islet cell transplantation offers hope for patients with type 1 diabetes by restoring insulin production. However, a major challenge remains: ensuring the transplanted cells survive and function effectively over time. Recent research has focused on various strategies to improve islet cell survival after transplantation, increasing the success rate of this promising treatment. The field is advancing rapidly, with breakthroughs in biomaterials, gene editing, and immunomodulation pushing the boundaries of what is possible. This article explores the core challenges facing islet transplantation and the innovative approaches researchers are taking to overcome them, ultimately aiming to make this therapy a durable, mainstream option for people living with type 1 diabetes.

Understanding Islet Cell Transplantation

Islet cell transplantation involves isolating insulin-producing beta cells from the pancreas of a deceased donor and infusing them into the liver of a recipient with type 1 diabetes. Once engrafted, these cells can sense blood glucose levels and secrete insulin accordingly, mimicking the natural regulatory function of a healthy pancreas. The procedure is typically performed under local anesthesia and involves a catheter inserted into the portal vein, which delivers the islets to the liver. Over weeks, the cells establish a blood supply and begin producing insulin. For many recipients, the result can be a dramatic reduction in severe hypoglycemic episodes and improved glycemic control, often allowing them to reduce or even discontinue external insulin injections. However, despite its life-changing potential, the procedure is not yet a standard cure. Long-term success remains limited, and most transplant recipients require multiple infusions to achieve sustained insulin independence. The primary bottleneck is the poor survival rate of the transplanted islet cells, which can drop by as much as 60–80% within the first days and weeks after transplantation.

Challenges to Islet Cell Survival

The primary obstacles to islet survival include immune rejection, lack of blood supply, and the hostile environment within the recipient's body. These factors can lead to inflammation, apoptosis, and cell death, reducing the effectiveness of the transplant. Understanding these barriers is critical to designing interventions that can protect the cells and extend their functional lifespan.

Immune Rejection

The recipient’s immune system often attacks the transplanted cells, perceiving them as foreign. Even with the use of immunosuppressive drugs, the immune response can be swift and destructive. Both the innate and adaptive arms of the immune system play roles: macrophages and neutrophils infiltrate the transplant site within hours, releasing pro-inflammatory cytokines that damage islet cells. Later, T cells and antibodies target donor antigens, leading to chronic rejection. Immunosuppressive regimens—typically including tacrolimus, sirolimus, and corticosteroids—help but come with significant side effects such as nephrotoxicity, increased infection risk, and metabolic disturbances. Moreover, these drugs do not guarantee long-term survival; many patients experience gradual loss of islet function over years.

Limited Blood Supply and Hypoxia

After transplantation, islet cells require rapid revascularization to receive oxygen and nutrients. Delays or failures in blood vessel growth can lead to cell death. In the liver, islets are deposited into the portal venous system, where they become lodged in small sinusoids. These sites are relatively hypoxic compared to the native pancreas, which has a rich capillary network. Islet cells are highly metabolically active and sensitive to oxygen deprivation. Without a robust and speedy revascularization process, the cells undergo hypoxic injury and necrosis. Experimental studies show that revascularization begins within days but can take up to two weeks; during this window, many islet cells are lost. Researchers are actively developing strategies to accelerate blood vessel formation and improve oxygen delivery to the graft site.

The Inflammatory Microenvironment

The immediate inflammatory response triggered by the transplant procedure itself also contributes to cell death. The instant blood-mediated inflammatory reaction (IBMIR) occurs when the infused islets come into contact with blood, activating the complement cascade and coagulation pathways. This leads to clot formation and the recruitment of immune cells to the islet surface, causing early destruction. Additionally, the liver’s resident immune cells, including Kupffer cells, release inflammatory cytokines that further compromise islet viability. The combination of hypoxia, immune attack, and inflammation creates a hostile microenvironment that challenges even the most robust islet preparations.

Innovative Strategies for Improvement

Researchers are exploring multiple approaches to enhance islet cell survival, each targeting a different aspect of the problem. These include encapsulation techniques, genetic modification, promotion of revascularization, and immunomodulation. Many of these strategies are being tested in combination to provide a multi-layered defense for the transplanted cells.

Encapsulation Techniques

Encapsulation involves encasing islet cells in biocompatible materials to protect them from immune attack. The goal is to create a semi-permeable barrier that allows oxygen, glucose, and insulin to pass through while blocking larger immune molecules and cells. Two main types exist: macroencapsulation, where many islets are placed in a large device (often implanted under the skin or in the peritoneum), and microencapsulation, where individual islets are coated with a thin layer of hydrogel, typically alginate derived from seaweed. Advances in alginate chemistry have produced formulations that reduce fibrotic overgrowth and maintain long-term permeability. Companies like ViaCyte (now part of Vertex Pharmaceuticals) are developing stem cell-derived islet cells encapsulated in devices that are now in clinical trials. However, challenges remain: the capsule can limit nutrient diffusion, and the foreign body response can eventually encapsulate the device itself, cutting off the islets. New biomaterials, such as modified alginate with triazole groups or zwitterionic coatings, show promise in reducing host reaction and improving graft survival in animal models.

Genetic Modification

Genetic modification offers a powerful tool to directly enhance islet resilience. Scientists are using techniques like CRISPR-Cas9 to edit islet cells before transplantation, inserting genes that confer resistance to immune rejection or improve metabolic function. For example, inserting genes for anti-apoptotic proteins (e.g., Bcl-2) or for enzymes that neutralize reactive oxygen species can help islets withstand the oxidative stress encountered in the liver. Researchers are also developing “immune-evasive” islets that lack major histocompatibility complex (MHC) class I molecules, making them invisible to T cells. Another approach involves expressing immunomodulatory molecules like PD-L1 or CTLA-4-Ig on the islet surface to induce local immune suppression without systemic side effects. A notable development is the use of genetically modified pig islets (xenotransplantation) that have been engineered to express human complement regulatory proteins, reducing hyperacute rejection. Early clinical trials with pig islets in New Zealand and elsewhere have shown some success, though long-term results remain limited.

Promoting Revascularization

To address the critical issue of limited blood supply, researchers are working on promoting rapid revascularization around the transplanted islets. This involves incorporating growth factors such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) into the transplant site. Strategies include coating islets with heparin-binding VEGF, embedding growth factor-releasing microspheres in the islet preparation, or using gene therapy to make islets themselves secrete angiogenic factors. Another innovative approach is co-transplanting islets with mesenchymal stem cells (MSCs), which naturally produce a range of trophic factors that support angiogenesis and immune modulation. Clinical studies have shown that MSCs can improve islet engraftment and function, and they are being tested in ongoing trials. Additionally, biomaterial scaffolds that mimic the extracellular matrix and release pro-angiogenic factors are being developed to create a supportive niche for the islets, both in the liver and in alternative sites like the omentum or subcutaneous space.

Immunomodulation

Immunomodulation aims to control the immune response more specifically than broad immunosuppression, reducing side effects while protecting the islets. Several strategies are under investigation. One involves inducing regulatory T cells (Tregs) that suppress effector T cells reactive to donor antigens. Infusions of expanded autologous Tregs alongside islet transplantation are being tested in early-phase clinical trials. Another approach uses co-stimulatory blockade agents like belatacept to inhibit T cell activation without the nephrotoxic effects of calcineurin inhibitors. Monoclonal antibodies against CD3, CD20, or complement components have shown promise in preclinical models. Furthermore, local immunomodulation—delivering immunosuppressive drugs directly to the graft site using slow-release polymers—can minimize systemic exposure. Researchers are also exploring tolerance induction protocols that use donor bone marrow or hematopoietic stem cell transplantation to create chimerism, where the recipient’s immune system accepts the donor tissue as self. While still experimental, these approaches could lead to long-term graft acceptance without the need for lifelong immunosuppression.

The Role of Hypoxia and Oxygen Delivery

Hypoxia is a central driver of islet cell death in the immediate post-transplant period. Even with revascularization efforts, the earliest days are critical. Therefore, researchers are also investigating direct oxygen supplementation methods. For example, macroencapsulation devices can be connected to an external oxygen source or fitted with oxygen-generating materials. One such device, the βAir (from Beta O2 Technologies), uses an internal oxygen chamber that is replenished via a subcutaneous port. Clinical trials have shown that this device can maintain human islet function for over a year, though it requires daily oxygen refills. Another approach uses perfluorocarbon emulsions, which can carry high amounts of oxygen and are infused with the islets to improve local oxygenation. Biodegradable oxygen-generating implants that slowly release oxygen through chemical reactions are also in development. These strategies aim to bridge the gap between transplant and revascularization, dramatically reducing the early loss of islet mass.

Alternative Transplantation Sites

While the liver has been the standard site for islet infusion, it is far from ideal. The liver is hypoxic, contains immune cells, and subjects islets to high concentrations of portal blood that may damage them. Researchers are exploring alternative sites such as the omentum, the subcutaneous space, the gastric submucosa, and even the bone marrow. The omentum is particularly promising because it has a rich blood supply and high capacity for angiogenesis. In preclinical studies and small clinical trials, islets transplanted into the omentum show improved survival and function. The subcutaneous space offers the advantage of ease of access and monitoring, but its limited vascularity requires modification with scaffolds or growth factors. Another exciting option is the use of a "bioartificial pancreas" device that houses islets in a protected environment, often implanted in the subcutaneous space, with ports for oxygen and nutrient delivery. These devices are moving toward clinical testing and could ultimately provide a safe, retrievable platform for islet transplantation.

Clinical Trials and Translational Progress

The progress in islet cell survival is being translated into the clinic. Several ongoing clinical trials are testing these strategies head-to-head. For example, the NCT03920397 trial is evaluating the use of a new encapsulation technology in patients with type 1 diabetes. Another trial is investigating the combination of islet transplantation with MSC co-infusion to improve outcomes. Data from these studies are expected in the coming years. Meanwhile, the Clinical Islet Transplantation Consortium (CIT) has established standardized protocols that have improved overall success rates, with many centers reporting insulin independence of over 50% at one year post-transplant. The introduction of newer immunosuppressive regimens, such as T-cell depleting agents and belatacept, has reduced the rate of graft loss. However, durability remains the key hurdle; by five years, only a minority of patients remain insulin-independent. Long-term studies are now focusing on identifying biomarkers of graft function and rejection, as well as refining patient selection to maximize benefit.

Future Outlook and Conclusion

Advances in biomaterials, gene editing, and immunology are paving the way for more durable and effective islet cell transplants. As research continues, the goal is to make this treatment a viable long-term solution for people with type 1 diabetes, reducing reliance on insulin injections and improving quality of life. The convergence of these technologies suggests that a functional cure may be achievable within the next decade. For instance, the University of Miami's Diabetes Research Institute is leading efforts to create a "protected cell product" using stem cell-derived islets housed in a biocompatible device that incorporates oxygen delivery and immunomodulation. Similarly, Vertex Pharmaceuticals is advancing a cell therapy program using stem cell-derived islets without encapsulation, relying on immunosuppression to protect the cells—and early results have been promising. The ultimate hope is to develop a product that either avoids immunosuppression entirely through encapsulation and tolerance induction, or that uses a patient’s own stem cells, eliminating rejection entirely. While challenges remain—including cost, scalability, and long-term safety—the pace of discovery is accelerating. For the more than 1.5 million Americans living with type 1 diabetes, these advances offer genuine hope for a life free from daily insulin injections and the burden of glucose monitoring. Researchers, funded in part by organizations like the JDRF and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), are committed to overcoming the final hurdles to bring this transformative therapy to the clinic.